Lonza Group Ag Total Assets 2012-2018 | LZAGY

Lonza Group Ag total assets from 2012 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Lonza Group Ag total assets for the quarter ending December 31, 2018 were $14.228B, a 105.23% increase year-over-year.
  • Lonza Group Ag total assets for 2017 were $14.015B, a 102.16% increase from 2016.
  • Lonza Group Ag total assets for 2016 were $6.932B, a 6.62% increase from 2015.
  • Lonza Group Ag total assets for 2015 were $6.502B, a 7.76% decline from 2014.
Lonza Group Ag Annual Total Assets
(Millions of US $)
2017 $14,015
2016 $6,932
2015 $6,502
2014 $7,048
2013 $7,061
2012 $7,576
2011 $7,949
Lonza Group Ag Quarterly Total Assets
(Millions of US $)
Q4 2018 $14,228
Q2 2018 $14,215
Q4 2017 $14,015
Q2 2017 $9,740
Q4 2016 $6,932
Q2 2016 $6,485
Q4 2015 $6,502
Q2 2015 $6,424
Q4 2014 $7,048
Q2 2014 $7,427
Q4 2013 $7,061
Q2 2013 $7,431
Q4 2012 $7,576
Q2 2012 $7,502
Q4 2011 $7,949
Q2 2011 $5,065
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $25.691B $5.566B
Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $148.090B 27.01
Medtronic (MDT) Ireland $143.599B 20.16
Stryker (SYK) United States $74.738B 25.13
Boston Scientific (BSX) United States $56.464B 26.65
Baxter (BAX) United States $40.084B 24.31
EssilorLuxottica Societe Anonyme (ESLOY) France $32.664B 0.00
Zimmer Biomet Holdings (ZBH) United States $29.619B 18.58
Terumo (TRUMY) Japan $27.722B 0.00
Coloplast (CLPBY) Denmark $25.121B 0.00
ResMed (RMD) United States $20.684B 38.16
Sunny Optical Technology (SNPTF) China $18.592B 0.00
Smith & Nephew SNATS (SNN) United Kingdom $18.588B 0.00
Bio-Rad Laboratories (BIO) United States $10.550B 50.64
Insulet (PODD) United States $10.476B 498.41
Canopy Growth (CGC) Canada $7.475B 0.00
Hill-Rom Holdings (HRC) United States $6.947B 20.47
Perrigo (PRGO) Ireland $6.812B 12.70
William Demant Holdings (WILYY) Denmark $6.665B 0.00
DiaSorin S.p.A (DSRLF) Italy $6.420B 0.00
Haemonetics (HAE) United States $6.037B 40.79
GN STORE NORD (GNNDY) Denmark $5.276B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $5.155B 0.00
Aurora Cannabis (ACB) Canada $3.920B 0.00
NuVasive (NUVA) United States $3.757B 29.59
ICU Medical (ICUI) United States $3.456B 22.41
GW Pharmaceuticals (GWPH) United Kingdom $3.380B 0.00
Neogen (NEOG) United States $3.369B 56.38
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.987B 0.00
Quidel (QDEL) United States $2.480B 23.54
National Vision Holdings (EYE) United States $2.179B 49.55
Agios Pharmaceuticals (AGIO) United States $1.976B 0.00
Cardiovascular Systems (CSII) United States $1.570B 0.00
InMode (INMD) Israel $1.293B 0.00
Aphria (APHA) $1.275B 0.00
VAREX IMAGING (VREX) United States $1.245B 28.70
AtriCure (ATRC) United States $1.109B 0.00
Phibro Animal Health (PAHC) United States $0.936B 17.53
Eagle Pharmaceuticals (EGRX) United States $0.863B 22.01
Lantheus Holdings (LNTH) United States $0.842B 21.04
NanoString Technologies (NSTG) United States $0.826B 0.00
TG Therapeutics (TGTX) United States $0.775B 0.00
Omeros (OMER) United States $0.669B 0.00
LeMaitre Vascular (LMAT) United States $0.662B 37.49
PetIQ (PETQ) United States $0.655B 16.01
HEXO (HEXO) $0.604B 0.00
Quanterix (QTRX) United States $0.589B 0.00
Cerus (CERS) United States $0.577B 0.00
Organigram Holdings (OGI) Canada $0.572B 0.00
OraSure Technologies (OSUR) United States $0.529B 31.74
Surmodics (SRDX) United States $0.527B 54.97
Owens & Minor (OMI) United States $0.454B 16.79
MacroGenics (MGNX) United States $0.404B 0.00
Utah Medical Products (UTMD) United States $0.383B 27.79
BioLife Solutions (BLFS) United States $0.341B 104.75
Meridian Bioscience (VIVO) United States $0.337B 11.62
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.328B 0.00
Zynex (ZYXI) United States $0.295B 33.33
Viemed Healthcare (VMD) United States $0.266B 0.00
Bovie Medical (APYX) United States $0.238B 0.00
United Health Products (UEEC) United States $0.185B 0.00
Vapotherm (VAPO) United States $0.183B 0.00
Repro-Med Systems (KRMD) United States $0.172B 0.00
Cytosorbents (CTSO) United States $0.149B 0.00
InfuSystems Holdings (INFU) United States $0.142B 0.00
Liberty Health Sciences (LHSIF) Canada $0.133B 0.00
Female Health (VERU) United States $0.131B 0.00
Fonar (FONR) United States $0.126B 8.87
Rockwell Medical (RMTI) United States $0.118B 0.00
Chimerix (CMRX) United States $0.101B 0.00
United-Guardian (UG) United States $0.085B 21.62
Chembio Diagnostics (CEMI) United States $0.080B 0.00
Nephros (NEPH) United States $0.072B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
MRI Interventions (MRIC) United States $0.053B 0.00
Surface Oncology (SURF) United States $0.048B 0.00
MTech Acquisition (KERN) United States $0.046B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
GUARDION HEALTH (GHSI) United States $0.020B 0.00
Senestech (SNES) United States $0.019B 0.00
Myomo (MYO) United States $0.012B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.008B 0.00
Akers Biosciences Inc (AKER) United States $0.004B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00